冯·希佩尔-林道(VHL)病全身治疗的探索之路:我们抵达终点了吗?
本文为个人观点文章,回顾VHL病局限期全身治疗历史并讨论HIF-2α抑制剂的应用问题。Belzutifan为第二代HIF-2α抑制剂,已获美英监管机构批准用于VHL病相关ccRCC、CNS-HB和pNET。作者强调需明确推荐情形与整体管理定位,并呼吁肿瘤内科医生加入多学科团队。
要点
- VHL病为常染色体显性遗传性肿瘤综合征,可累及ccRCC、CNS-HB、视网膜血管瘤、嗜铬细胞瘤和pNET。
- Belzutifan为第二代HIF-2α抑制剂,已获美英监管机构批准用于VHL病相关ccRCC、CNS-HB和pNET。
- 作者认为需明确HIF-2α抑制剂推荐情形及其在VHL病整体管理中的定位,并让肿瘤内科医生参与多学科团队。
核心结论
- Belzutifan获美英监管机构批准是VHL病全身治疗的重要进展,但需考虑这些药物在何种情形下被推荐以及如何融入VHL病整体管理。
- VHL病是未来类似情形的理想范式。
研究设计与样本
- 本文为个人观点文章,回顾局限期VHL病全身治疗历史并讨论HIF-2α抑制剂相关的开放问题。
主要发现
- VHL病由VHL基因致病性种系突变引起,为常染色体显性遗传性肿瘤综合征,良恶性肿瘤外显率高。
- VHL病管理涉及终身影像学和生化监测,常导致反复手术干预,造成显著发病率和死亡率。
- 能够预防或减少手术干预需求的全身治疗可能改善患者临床结局和生活质量。
- Belzutifan为第二代小分子HIF-2α抑制剂,最近获美国和英国监管机构批准用于VHL病相关ccRCC、CNS-HB和pNET。
临床怎么用
- 作者认为需考虑HIF-2α抑制剂在何种情形下被推荐以及如何融入VHL病整体管理。
- 作者认为未来需让肿瘤内科医生参与多学科团队。
局限性
- 本文为个人观点文章。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pathogenic germline mutations in VHL gene cause von Hippel-Lindau (VHL) disease, an autosomal dominant hereditary cancer syndrome associated with high penetrance of benign and malignant neoplasms, including clear cell renal cell carcinoma (ccRCC), central nervous system haemangioblastomas (CNS-HB), retinal angiomas, phaeochromocytomas and pancreatic neuroendocrine tumours (pNET). Management of VHL disease involves lifelong radiological and biochemical surveillance, often leading to repeat surgical intervention causing significant morbidity and mortality. Systemic therapy that prevents or reduces the need for surgical intervention could improve clinical outcomes and quality of life for affected individuals. Belzutifan is a second-generation small molecule hypoxia-inducible factor 2α (HIF-2α) inhibitor recently approved by US and UK regulators for the treatment of VHL (disease)-associated ccRCC, CNS-HB and pNET. While this is a welcome step forward, it is vital that we consider in what circumstances these drugs are recommended and how they fit into the overall management of VHL disease. In this personal view article, we reflect on the history of the use of systemic therapy in localised VHL disease and consider open questions relating to the use of HIF-2α inhibitors, including the need to involve medical oncologists in the multidisciplinary team moving forward. Indeed, VHL disease is the perfect paradigm for similar settings in the future.
引用
- Shepherd STC, Drake WM, Turajlic S, et al. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet? Eur J Cancer. 2022. PMID: 36708612. doi:10.1016/j.ejca.2022.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。